Dianthus Therapeutics, Inc. DNTH
Updated: 16 Jun 2026
No signal published yet
We already track Dianthus Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Dianthus Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dianthus Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On May 13, 2024, Dianthus reported its first quarter financial results and provided an update on the Phase 2 MaGic trial for generalized Myasthenia Gravis. The company stated that its cash runway is expected to extend into the second quarter of 2027. Data from the Phase 2 trial is anticipated in the second half of 2025.
What Firelda Watch includes for Dianthus Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Dianthus Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Dianthus Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more